secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0000875320-23-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q1 product rev $2.37B (+13%); net income down 8% on higher R&D; FY23 guidance unchanged
--------------------------------------------------------------------------------

- Product revenue $2.37B (+13% YoY); U.S. $1.40B (+3%), ex-U.S. $971M (+33%).
- GAAP net income decreased 8% YoY; cash and marketable securities $11.5B at quarter end.
- FY23 product revenue guidance reaffirmed at $9.55-9.7B; combined GAAP R&D and SG&A unchanged at $4.35-4.6B.
- TRIKAFTA approved in U.S. for CF children aged 2-5; completed rolling BLA submissions for exa-cel in U.S.
- Pipeline: VX-548 acute pain Phase 3 enrollment ongoing; inaxaplin AMKD Phase 2/3; VX-880 T1D data expected at ADA June 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532023000010/0000875320-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532023000010/vrtx-20230501.htm
  HTML page:      https://secwatch.observer/filing/0000875320-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer